Proprietary arabinogalactan extract increases antibody response to the pneumonia vaccine: a randomized, double-blind, placebo-controlled, pilot study in healthy volunteers

Table 2 Effects of the 23-valent vaccine on Pneumococcal IgG antibodies

Antibody subtype	Day 0 Mean ± SD	Day 51 Mean ± SD	Day 72 Mean ± SD	Change Days 0-51	Change Days 0-72
Type 4	0.45 ± 0.64	2.21 ± 3.15	5.84 ± 7.35	0.023	0.042
Type 6B	0.95 ± 1.51	5.18 ± 6.64	5.19 ± 7.06	0.001	0.020
Type 9V	1.32 ± 4.10	6.07 ± 7.34	5.08 ± 5.25	0.129	0.095
Type 14	1.79 ± 2.56	9.91 ± 8.54	8.86 ± 8.59	0.000	0.006
Type 18C	0.72 ± 1.35	5.06 ± 5.80	4.93 ± 5.26	0.018	0.006
Type 19F	1.10 ± 2.94	7.02 ± 7.28	6.65 ± 7.26	0.011	0.015
Type 23F	1.08 ± 1.87	4.32 ± 4.62	4.55 ± 5.23	0.017	0.006

Increases in levels of antibody subtype as observed in the placebo group (n = 24) following inoculation with the 23-valent pneumococcal vaccine which took place on Day 30. Data are means (μg/dl) ± standard deviations on Days 0, 51 and 72. P-values for the changes between baseline and days 51 and 72 are in the right hand columns.

ISSN: 1475-2891